Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 7/20 | 0.84 |
| ▸ | MAOA | P21397 | 8/20 | 0.54 |
| ▸ | MAOB | P27338 | 8/20 | 0.54 |
| ▸ | PRKCI | P41743 | 1/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086223 | 0.91 | HSD17B1 (1.00) | HSD17B1MAOAMAOBPRKCIPGR | |
| SCHEMBL4085867 | 0.81 | HSD17B1 (1.00) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL4090561 | 0.79 | HSD17B1 (1.00) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL9492189 | 0.78 | HSD17B1 (0.61) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL3953461 | 0.76 | HSD17B1 (0.71) | HSD17B1CYP1A2 | |
| SCHEMBL8170785 | 0.75 | HSD17B1 (0.71) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL3021186 | 0.75 | HSD17B1 (0.74) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL13678958 | 0.74 | HSD17B1 (0.75) | HSD17B1CYP1A2 | |
| SCHEMBL14013915 | 0.73 | MAOA (0.56) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL7584101 | 0.73 | HSD17B1 (0.73) | HSD17B1MAOAMAOBPRKCIBAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | HSD17B1 4/4885MAOA 470/4885MAOB 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.